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To the Editor: Drug-eluting stents (DES) represent a breakthrough
in interventional cardiology but have been unable to reduce the
incidence of stent thrombosis (1–2). Delayed endothelization and
late vessel remodeling might stimulate thrombus deposition and
DES thrombosis especially in “real-world” situations (1–2). There-
fore, a prolonged dual antiplatelet regimen has been advocated in
these patients (1–2). Predisposing factors, mechanisms, and man-
agement of patients suffering episodes of DES thrombosis are not well
established. Intravascular ultrasound (IVUS) provides a unique tool to
optimize stent implantation, but its potential use to guide re-
interventions in patients suffering DES thrombosis remains unknown.
In this prospective study, we sought to assess the value of IVUS in
patients suffering DES thrombosis.
Between January 2004 and June 2006, of 1,974 consecutive
patients undergoing DES implantation at our institution, 26
(1.3%) experienced angiographic DES thrombosis and 12 were
included in the IVUS study. Our protocol in patients experiencing
stent thrombosis has been previously described (3). Briefly, any
patient with a clinical suspicion of DES thrombosis was immedi-
ately brought to the cardiac catheterization laboratory. After
reviewing previous coronary intervention, selected angiographic
views were obtained after intracoronary nitroglycerin (0.2 mg)
administration. Heparin was given as an intracoronary bolus (70
IU/kg) associated (unless contraindicated) with adjuvant glyco-
protein IIb/IIIa inhibitors. The IVUS study was obtained before
and after intervention (3). Intravascular ultrasound catheters
with 40-MHz mechanical transducers and a 0.5-mm/s motor-
ized pull-back device were used. Balloon angioplasty was
performed, taking into account IVUS findings, to optimize
procedural results. Additional stents were implanted for subop-
timal results or inflow/outflow lesions. Personnel blinded to
clinical and angiographic data performed qualitative and quan-
titative IVUS analyses (3). Malapposition was defined when at
least 1 DES strut, not encompassing a side branch, was not in
contact with the underlying vessel wall (3). A validated system
for volumetric IVUS analysis (EchoScan, TOMTEC, Boulder,
Colorado) was used for 3-dimensional reconstruction (3). Stent
under-expansion was defined as minimum stent area 80% of
mean proximal/distal reference areas. The MUSIC (Multicenter
Ultrasound Stenting in Coronaries) criteria for optimal expansion
were evaluated (3). Data were analyzed with the SPSS software
(SPSS Inc., Chicago, Illinois); categorical variables (n, %) were
compared with the Fisher exact test, and continuous data (mean
SD) with the 2-tailed, unpaired (demographic) or paired (pre- vs.
post-intervention), Student t test. A p value 0.05 was consid-
ered statistically significant.
Table 1 compares baseline characteristics of patients with and
without DES thrombosis. Patients suffering from DES throm-
bosis were younger, more frequently smokers and treated during
an acute myocardial infarction, had lower ejection fraction, and
their lesions were more complex.
Of the 12 patients included in the IVUS study, 10 presented
with ST-segment elevation myocardial infarction and 2 were in
cardiogenic shock. Median time between DES implantation and
thrombosis was 7 days, and 5 patients had late (30 days)
thrombosis. Of interest, 3 patients showed patent conventional
stents in other vessels.
On IVUS (Table 2), an occlusive thrombus was seen in all
patients. Most DES presented severe under-expansion, and all
patients had significant inflow/outflow disease. Malapposition was
detected in 6 (50%) patients (3 subacute, 3 late thrombosis), and
major side branches jailed by the stent were seen in 8 (67%)
patients. Optimal criteria of deployment were not present in any
patient. Imaging time before intervention was 196  55 s. Owing
to pre-intervention IVUS findings, either larger balloon diameters
(7 patients) or higher inflation pressures (9 patients) were used in
all patients. A thrombectomy device was used in 4 cases, and
additional stent implantation in 4. Glycoprotein IIb/IIIa inhibitors
were administered in all but 1 patient. After the procedure, final
DES minimal area (12  4 mm2 vs. 9  3 mm2, p  0.008),
expansion (91  12% vs. 74  12%, p  0.002), and volume
(491  326 mm3 vs. 286  183 mm3, p  0.018) significantly
improved compared with pre-interventional values. After reinter-
vention, no patient showed incomplete apposition and all but 2
patients fulfilled the MUSIC criteria. However, some residual
lining thrombus could still be visualized in all patients (78  48
mm3 vs. 142  90 mm3 before intervention, p  0.02). Before
intervention, 51  22% of total stent volume was occupied by
thrombus, but only 17  7% of stent volume had thrombus after
intervention (p  0.001).
The DES thrombosis occurred in 1 patient that had prema-
turely stopped clopidogrel therapy and in another patient in whom
aspirin was withdrawn for noncardiac surgery, but 7 patients
suffered DES thrombosis despite adequate antiplatelet therapy.
Resistance to aspirin was demonstrated in 3 patients, and 1 patient
had thrombocytosis. One patient with an IVUS-detected coronary
aneurysm obtained complete apposition after aggressive balloon
dilation; however, he died from respiratory arrest secondary to lung
carcinoma. Eleven patients developed large myocardial infarctions
(creatine phosphokinase 1,863  1,089 IU) and were discharged
11  9 days after admission.
The major findings of this study are the following: 1) an
occlusive thrombus is readily visualized with IVUS in all patients
with DES thrombosis; 2) most patients suffering this dreadful
complication have severely under-expanded DES associated with
inflow-outflow disease; 3) additional mechanical factors (malap-
position, side branch exit) are common; and 4) IVUS findings
might be readily used to guide and optimize results of repeated
procedures.
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Concerns of higher thrombosis rates have recently been
raised with the widespread use of DES with expanding indica-
tions (1–2). Several studies have analyzed predisposing factors
for DES thrombosis; these include premature platelet discon-
tinuation, small final lumen diameter, acute myocardial infarc-
tion, bifurcation stenting, diabetes, renal failure, low ejection
fraction, and in-stent restenosis (1–2). Our results, in the
complete series of patients treated with DES, confirm the
importance of clinical and angiographic factors to identify
patients at higher risk for DES thrombosis.
Three previous studies have analyzed IVUS findings in patients
suffering bare-metal stent thrombosis. In a large retrospective
multicenter study (4), abnormal IVUS findings (under-expansion,
malapposition, inflow/outflow disease, dissections, or thrombus)
were detected immediately after the procedure in 94% of patients
subsequently suffering stent thrombosis. Of interest, angiography
failed to detect these abnormal findings. Cheneau et al. (5)
retrospectively assessed post-intervention IVUS findings in 21
patients with stent thrombosis; at least 1 potential mechanical
cause for thrombosis was identified in 78% of lesions. Finally, in
a previous prospective study (3) we used IVUS during episodes
of bare-metal stent thrombosis. Stent under-expansion, dissec-
tions, malapposition, and inflow/outflow disease were common.
Notably, IVUS guidance was valuable to optimize repeated
interventions.
The role of IVUS to predict DES thrombosis, however, remains
controversial (6–9). Studies suggest that late malapposition is
more frequently found after DES than after bare-metal stent
implantation. However, in most of these studies (6–8) DES
malapposition was considered to be just a pure IVUS finding
without clinical repercussions. Fujii et al. (8) evaluated 15 patients
experiencing DES thrombosis with IVUS. Drug-eluting stent
under-expansion and residual reference segment stenosis were
associated with DES thrombosis, but DES malapposition was not.
Conversely, a recent report by Cook et al. (9) suggested that
incomplete apposition might indeed constitute a risk factor for
“very late” DES thrombosis. This finding was visualized in 10 of
13 patients (77%) with this complication. However, in these 2
previous studies (8,9) thrombus features, procedural results, and
the possibility of IVUS guidance during the repeated intervention
were not described.
In the current IVUS study the high rate of DES malappo-
sition and major side branches jailed by DES is of major
concern and suggests a potential pathophysiologic link with
DES thrombosis. Finally, our findings underscore the critical
role of IVUS to guide repeated procedures in this challenging
setting. Despite the use of aggressive dilations, residual lining
thrombi were uniformly detected after these rescue procedures.
However, IVUS guidance led to a significant improvement in all
expansion parameters.
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Table 1
Baseline Clinical, Angiographic, and Procedural
Characteristics at the Time of DES Implantation
Characteristic
No Thrombosis
(n  1,948)
Thrombosis
(n  26)
IVUS-Thrombosis
(n  12)
Age (yrs) 64 12 59 12* 62 11
Female 574 (30) 5 (19) 3 (25)
Diabetes mellitus 789 (41) 11 (42) 3 (25)
Hyperlipidemia 1,098 (56) 11 (42) 2 (17)
Hypertension 1,183 (61) 14 (54) 7 (58)
Ever smoked 1,118 (57) 20 (77)* 9 (75)
Prior myocardial infarction 1,096 (56) 19 (73) 9 (75)
Acute myocardial infarction 280 (14) 8 (31)* 4 (33)
Stable angina 932 (48) 9 (34) 1 (8)
LVEF (%) 62 14 52 14† 55 14
Glycoprotein IIb/IIIa inhibitors (%) 290 (15) 3 (13) 2 (17)
Lesions (n  2,772) (n  30) (n  12)
Left main 50 (1.8) 0 (0) 0 (0)
Left anterior descending 1,382 (50) 19 (64) 8 (67)
Left circumflex 522 (19) 4 (13) 1 (8)
Right coronary 750 (27) 7 (23) 3 (25)
B2-C lesion 1,995 (72) 24 (83) 8 (67)
Restenotic lesion 239 (9) 8 (27)† 3 (25)
Thrombus 342 (12) 8 (27)* 2 (17)
Stent length (mm) 21 10 26 17 24 20
Lesion length 15 7 20 12‡ 17 15
% diameter stenosis 85 12 89 11* 84 13
Maximal pressure (atm) 16 3 16 3 15 2
Maximal balloon diameter (mm) 2.99 0.4 3.04 0.6 2.94 0.4
*p  0.05 (thrombosis vs. no thrombosis). †p  0.01 (thrombosis vs. no thrombosis). ‡p  0.053 (thrombosis vs. no thrombosis).
DES  drug-eluting stent; IVUS  intravascular ultrasound; LVEF  left ventricular ejection fraction.
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Letters to the Editor
Plasma Brain Natriuretic
Peptide-Guided Therapy
Not Yet Justified
A recent study by Jourdain et al. (1) published in the Journal
suggests that a brain natriuretic peptide (BNP)-guided therapeutic
strategy was superior to a clinically guided approach in patients
with chronic heart failure (CHF). A total of 200 New York Heart
Association functional class II to III patients considered optimally
treated by CHF specialists were randomized to medical treatment
according to current guidelines (2) or a goal of decreasing BNP
plasma levels to 100 pg/ml. During a median follow-up of 15
months, significantly fewer patients in the BNP group reached the
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